Antheia Appoints Eric d’Esparbes as Chief Financial Officer
Antheia, the next-generation pharmaceutical ingredient producer with a mission to end drug shortages, appointed Eric d’Esparbes as Chief Financial Officer.
Prior to joining Antheia, Eric served as Chief Financial Officer at Biora Therapeutics. Before that, he was the Chief Financial Officer of Progenity. Throughout his career, he has held various financial leadership roles at organizations, including Innoviva, Joule Unlimited, AEI Services, and Meiya Power Company.
Eric earned a Bachelor of Business Administration, International Finance from the University of Montreal’s Business School H.E.C. Montreal.
Executive Search Partnership: Antheia
Partners Suzanne Zebedee Ph.D. and Joe Olson are proud to partner with Antheia on this Chief Financial Officer appointment. Learn more about ON Partners by downloading our recent 2025 CEO Report, exploring multi-faceted pathways to the CEO role and 2024 Private Equity Talent Trends Report, which unveils the five key themes reshaping executive talent strategies in private equity.
Antheia is the next-generation pharmaceutical ingredient producer with a mission to end drug shortages. Using advanced biosynthesis and fermentation technology, Antheia’s biomanufacturing platform enables rapid, efficient, agile, and on-demand production of key starting materials (KSMs) and active pharmaceutical ingredients (APIs) that are critical to public health. This highly flexible approach supports the needs of a growing society and improves global access to essential medicines. Founded in 2015, Antheia has grown into a commercial stage company with its first product to market, an active customer pipeline, and near-term product launches. For more information on how Antheia is transforming pharmaceutical supply chains, visit www.antheia.bio.
To learn more about partnering with our executive search firm, meet our executive search consultants.
